Results 161 to 170 of about 2,888,442 (218)

TRPML1 agonist ML‐SA5 attenuates pulmonary fibroblast activation by suppressing mTOR and restoring autophagic flux

FEBS Open Bio, EarlyView.
TGF‐β1 stimulation downregulates lysosomal channel TRPML1 in pulmonary fibroblasts. The TRPML1 agonist ML‐SA5 suppressed fibroblast‐to‐myofibroblast activation and collagen production. Mechanistically, ML‐SA5 inhibited mTOR phosphorylation, restored autophagic flux, and its effects were enhanced by rapamycin (mTOR inhibitor) and reversed by MHY1485 ...
Jiatong Yao, Xiaoting Kang, Lulu Meng, Shaoxuan Zhang, Qiujie Li, Jinyu Zhou, Mengyue Xue, Chu Li, Hua Zhu, Pengzhou Hang, Jing Zhao   +10 more
wiley   +1 more source

Age-Related Volumetric Changes of the Posterior Cranial Fossa and its Structures in Stroke Patients. [PDF]

Cerebellum
Rafaelian A, Cantré D, Dubinski D, Baki E, Beutel TM, Dinc N, Dremel J, Etminan N, Freiman TM, Ferdowssian K, Gessler F, Güresir E, Hackenberg KAM, Hemmer B, Hernández-Durán S, Hlaing ZY, Jankovic D, Kramer A, Krieg SM, Nabo WH, Naser P, Neumeister A, Ringel F, Rohde V, Samoylenko D, Marin-Sanabria D, Schäfer JH, Schuss P, Schwake M, Senft C, Thavarajasingam SG, Thiel M, Vajkoczy P, Vychopen M, Wach J, Walter J, Wunderlich S, Wittstock M, Won SY.   +38 more
europepmc   +1 more source

Understanding and Mitigating the Risk of Accelerated Biological Aging in Survivors of Cancer: A Scoping Review

Aging and Cancer, EarlyView.
Cancer treatment is associated with measurable acceleration of biological aging across epigenetic, telomere, senescence, and immune biomarkers. However, biomarker validation and interventional strategies remain limited, especially in hematologic malignancies, underscoring the need for standardized multi‐omic aging assessments and adequately powered ...
Moataz Ellithi, Emily Herdman, Danielle Westmark, Vijaya R. Bhatt   +3 more
wiley   +1 more source

Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).

JAMA Oncol
Bozorgmehr F, Chung I, Behnisch R, Weykamp F, Adeberg S, Overbeck T, El Shafie R, Maguire N, Koerber SA, Buchmeier EL, Hammer-Hellmig M, Gauler T, Pöttgen C, Wermke M, Troost EGC, Kokowski K, Röper B, Reinacher-Schick A, Consdorf NS, Ulmer M, Müller AC, Wehler T, Hey-Koch S, Alt J, Stockinger M, Kuon J, Bischof M, Lamprecht B, Geinitz H, Lerchenmüller C, Kriz J, Rauter M, Raunik W, Schmidt B, Stupavsky A, Kropf-Sanchen C, Schmidtke-Schrezenmeier G, Wiegel T, Tufman A, Manapov F, Merling M, Heussel CP, Polke M, Reck M, Al-Batran SE, Thomas M, Christopoulos P, Rieken S.   +47 more
europepmc   +1 more source

Association of oral anticoagulation persistence and health-related quality of life in stroke survivors with atrial fibrillation: long-term results of the Berlin atrial fibrillation registry. [PDF]

Neurol Res Pract
Steindorf-Sabath L, Olma MC, Tütüncü S, Kunze C, Grittner U, Heege J, Dietzel J, Schurig J, Heuschmann PU, Endres M, Haeusler KG.   +10 more
europepmc   +1 more source

Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants

Annals of Clinical and Translational Neurology, EarlyView.
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold, Krzysztof W. Selmaj, Regina Berkovich, Jeffrey A. Cohen, Giancarlo Comi, Eva K. Havrdová, James K. Sheffield, Hetal Desai, Chun‐Yen Cheng, Jon V. Riolo, Andrew Thorpe, Erik DeBoer, Bruce A. C. Cree   +12 more
wiley   +1 more source

Correction: Attitudes Toward Digital Planetary Health Before and After a Lecture Series on Environmental Awareness and Future Visions: Repeated Cross-Sectional Survey Study Regarding Twin Transformation. [PDF]

JMIR Med Educ
Nitsche J, Busse TS, Schmalen S, Otte I, Ehlers JP.   +4 more
europepmc   +1 more source

The Role of Calcitonin Gene‐Related Peptide in High‐Altitude Headache: A Prospective Field Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective High‐altitude headache (HAH) is a common neurological condition associated with rapid ascent to high altitude. The pathophysiological mechanisms underlying HAH remain incompletely understood. Calcitonin gene‐related peptide (CGRP), a neuropeptide implicated in migraine pathophysiology, may play a key role in the pathophysiology of ...
Roman Schniepp, Ludwig Karrasch, Helena Breitenstein, Andreas Straube, Katharina Kamm   +4 more
wiley   +1 more source

Dystonia 3×3: A Training Guideline for Beginners in Botulinum Neurotoxin Treatment of Cervical Dystonia. [PDF]

Toxins (Basel)
Paus S, Funke A, Hamacher J, Haslinger B, Heckelmann J, Ip CW, Jost WH, Kivi A, Klebe S, Lee JI, Lohmann E, Mack F, Schramm A, Stenner A, Tacik P, Walter U, Weise DT.   +16 more
europepmc   +1 more source